The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.
The non-profit CISCRP conducting interviews.. Please see below for more info
The Center for Information and Study on Clinical Research Participation (CISCRP) is an independent non-profit organization, dedicated to including the voice of the community in the clinical research process. As part of our mission, we regularly engage with affected individuals and families through patient (or community) advisory board meetings and interviews, global surveys, and workshops to include the community voice in research endeavors.
At this time, CISCRP, together with a pharmaceutical company, is planning a virtual interview project among patients diagnosed with locally advanced or metastatic cancer.
What is the purpose of this interview project?
During this 75-minute interview, you will be asked to share your personal experiences undergoing chemotherapy and targeted infusion therapy – specifically your experiences, before, during and after receiving treatment. This feedback will help the pharmaceutical company improve experiences for future study participants enrolled in clinical trials for this condition.
The goal of the interview is not to recruit for a clinical trial, but rather to learn from patients and their families how to best create a clinical trial that addresses the unique needs of individuals living with this condition and undergoing treatment.
Who can participate?
CISCRP is looking for patients and/or care partners* who feel comfortable sharing their experiences living with, or caring for someone with, locally advanced or metastatic cancer.
*If caregivers are interested in participating, they will be asked to take part with their loved one.
– Individuals 18+ years of age who have been diagnosed with locally advanced or metastatic cancer
– Ideally seeking individuals diagnosed with gastric cancer, gastroesophageal (GEJ) cancer, pancreatic cancer, colorectal cancer, ovarian cancer, melanoma, bladder cancer, esophageal cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), breast cancer, head and neck cancer or NSCLC
– Must have received or be currently receiving infused chemotherapy treatment
– Ideally have also received or currently be receiving targeted infusion therapy (e.g., Herceptin, Opdivo, Keytruda)
– Reside in the United States
When would the interview take place and what would it be like to participate?
This virtual interview would take place in July 2023. The meeting will be conducted virtually using an online platform (Zoom) as one, 75-minute meeting. As a thank you for your time, CISCRP will provide an honorarium to those who are eligible and participate.
If you are interested in participating in this opportunity or have any additional questions, please contact:
Project Manager, Research Services |Center for Information & Study on Clinical Research Participation (CISCRP)
Phone: 617-725-2750 x 415
Email: [email protected]
You must be logged in to reply to this topic.
About the MRF Patient Forum
The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.
The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.